These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2056331)

  • 21. Spinal cholinergic mechanisms.
    Gillberg PG; Askmark H; Aquilonius SM
    Prog Brain Res; 1990; 84():361-70. PubMed ID: 2267308
    [No Abstract]   [Full Text] [Related]  

  • 22. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
    Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
    Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cerebrovascular role of the cholinergic neural system in Alzheimer's disease.
    Van Beek AH; Claassen JA
    Behav Brain Res; 2011 Aug; 221(2):537-42. PubMed ID: 20060023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurobiological studies of transmitter systems in aging and in Alzheimer-type dementia.
    Price DL; Kitt CA; Struble RG; Whitehouse PJ; Cork LC; Walker LC
    Ann N Y Acad Sci; 1985; 457():35-51. PubMed ID: 2869729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.
    Quirion R
    J Psychiatry Neurosci; 1993 Nov; 18(5):226-34. PubMed ID: 8297921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited.
    Ladner CJ; Lee JM
    J Neuropathol Exp Neurol; 1998 Aug; 57(8):719-31. PubMed ID: 9720487
    [No Abstract]   [Full Text] [Related]  

  • 27. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders.
    Whitehouse PJ; Kellar KJ
    J Neural Transm Suppl; 1987; 24():175-82. PubMed ID: 2960781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases.
    Perry EK; Perry RH; Smith CJ; Dick DJ; Candy JM; Edwardson JA; Fairbairn A; Blessed G
    J Neurol Neurosurg Psychiatry; 1987 Jun; 50(6):806-9. PubMed ID: 2956364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paying attention to your acetylcholine, Part 2: the function of nicotinic receptors.
    Stahl SM
    J Clin Psychiatry; 2000 Sep; 61(9):628-9. PubMed ID: 11030481
    [No Abstract]   [Full Text] [Related]  

  • 31. Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
    Anderkova L; Barton M; Rektorova I
    Mov Disord; 2017 Jun; 32(6):917-922. PubMed ID: 28256044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease--a stereological approach.
    Banerjee C; Nyengaard JR; Wevers A; de Vos RA; Jansen Steur EN; Lindstrom J; Pilz K; Nowacki S; Bloch W; Schröder H
    Neurobiol Dis; 2000 Dec; 7(6 Pt B):666-72. PubMed ID: 11114264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
    Chan-Palay V
    J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pathological study of the association between Lewy body disease and Alzheimer's disease.
    Gibb WR; Mann DM; Mountjoy CQ; Lees AJ
    Adv Neurol; 1990; 53():55-9. PubMed ID: 2173375
    [No Abstract]   [Full Text] [Related]  

  • 35. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380.
    Pimlott SL; Piggott M; Owens J; Greally E; Court JA; Jaros E; Perry RH; Perry EK; Wyper D
    Neuropsychopharmacology; 2004 Jan; 29(1):108-16. PubMed ID: 12955099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.
    Whitehouse PJ
    Adv Neurol; 1987; 45():393-7. PubMed ID: 2881448
    [No Abstract]   [Full Text] [Related]  

  • 37. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups.
    Bird TD; Stranahan S; Sumi SM; Raskind M
    Ann Neurol; 1983 Sep; 14(3):284-93. PubMed ID: 6227276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical evidence of neuroprotection by cholinesterase inhibitors.
    Akaike A
    Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S8-11. PubMed ID: 16772755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebral ageing, neurotransmitters and therapeutic implications.
    Siow BL
    Singapore Med J; 1985 Apr; 26(2):151-3. PubMed ID: 2863876
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuronal nicotinic acetylcholine receptor-cholesterol crosstalk in Alzheimer's disease.
    Barrantes FJ; Borroni V; Vallés S
    FEBS Lett; 2010 May; 584(9):1856-63. PubMed ID: 19914249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.